(R)-2-bromo-6-phthalimidohexanoic acid | 5107-16-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (R)-2-bromo-6-phthalimidohexanoic acid
• 英文别名: 2-bromo-6-phthalimidohexanoic acid；2-bromo-6-phthalimidocaproic acid；2-bromo-6-phtaloyl caproic acid；2-bromo-6-phthalimido-hexanoic acid；2-Brom-6-phthalimido-hexansaeure；2-bromo-6-phthaloyl caproic acid；2-bromo-6-(1,3-dioxoisoindol-2-yl)hexanoic acid
• CAS: 5107-16-4
• 化学式: C₁₄H₁₄BrNO₄
• 分子量: 340.173
• InChiKey: IZPACYFLJIDSKN-UHFFFAOYSA-N

物化性质

• 熔点：
  151-153 °C
• 沸点：
  490.7±35.0 °C(Predicted)
• 密度：
  1.586±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  74.7
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-2-bromo-6-phthalimidohexanoic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 S-[6-(1,3-dioxoisoindol-2-yl)-1-[[(2S)-4-methyl-1-[[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl] ethanethioate
  参考文献：
  名称：

  Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety

  摘要：

  The in vitro potency of orally-active mercaptoacyl matrix metalloproteinase inhibitors is increased by the introduction of appropriate substituents on the mercaptoacyl moiety. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10069-5
• 作为产物：
  描述：

  lysine 在 硫酸 、 potassium bromide 、 sodium nitrite 作用下， 生成 (R)-2-bromo-6-phthalimidohexanoic acid
  参考文献：
  名称：

  Mercaptoacyl matrix metalloproteinase inhibitors: The effect of substitution at the mercaptoacyl moiety

  摘要：

  The in vitro potency of orally-active mercaptoacyl matrix metalloproteinase inhibitors is increased by the introduction of appropriate substituents on the mercaptoacyl moiety. (C) 1997 Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(97)10069-5

文献信息

• Synthesis and angiotensin converting enzyme inhibitory activity of 1,5-benzothiazepine and 1,5-benzoxazepine derivatives. II.
  作者：KATSUMI ITOH、MASAKUNI KORI、YOHIYUKI INADA、KOHEI NISHIKAWA、YUTAKA KAWAMATSU、HIROSADA SUGIHARA

  DOI：10.1248/cpb.34.2078

  日期：——

  A series of (R)-3-amino-4-oxo-2, 3, 4, 5-tetrahydro-1, 5-benzothiazepine-5-acetic acids (4 and 13)and (S)-3-amino-4-oxo-2, 3, 4, 5-tetrahydro-1, 5-benzoxazepine-5-acetic acids (5 and 14) having an(S)-ω-amino-1-carboxyalkylamino group at the 3-position was prepared as part of our search for long-acting angiotensin converting enzyme (ACE) inhibitors. A number of derivatives had potent in vitro and in vivo ACE inhibitory activities. The structure-activity relationship of the series indicated that the duration of in vivo ACE inhibitory activity depends on the length of the carbon chain in the ω-aminoalkylamino substituent at the 3-position. The most prolonged activity was observed with (S)-8-amino-1-carboxyoctylamino derivatives (4d and 5d).

  一系列具有(S)-ω-氨基-1-羧基烷胺基的(R)-3-氨基-4-氧代-2,3,4,5-四氢-1,5-苯并噻二嗪-5-乙酸(4和13)以及(S)-3-氨基-4-氧代-2,3,4,5-四氢-1,5-苯并噁二嗪-5-乙酸(5和14)作为我们寻找长效血管紧张素转换酶(ACE)抑制剂的一部分被合成。多个衍生物显示出强大的体外和体内ACE抑制活性。该系列化合物的结构-活性关系表明，体内ACE抑制活性的持续时间取决于3-位上ω-氨基烷胺取代基的碳链长度。具有最长活性的是(S)-8-氨基-1-羧基辛胺基衍生物(4d和5d)。
• N-carboxymethyl substituted benzolactams as inhibitors of matrix metalloproteinase
  申请人：——

  公开号：US20020095035A1

  公开（公告）日：2002-07-18

  The present invention provides a method of inhibiting matrix metallo-proteinases (MMPs) in a patient in need thereof comprising administering to the patient an effective matrix metalloproteinase inhibiting amount of the N-carboxymethyl substituted benzolactams of formula (1): 1 wherein A is —OH or —NRR′. Such inhibitors are useful in treating neoplasms, atherosclorosis, and chronic inflammatory diseases. The present invention also provides novel N-carboxymethyl substituted benzolactams of formula (1a): 2 wherein A is —NRR′.

  本发明提供了一种抑制需要患者体内基质金属蛋白酶（MMPs）的方法，包括向患者施用N-羧甲基取代苯并内酰胺的有效基质金属蛋白酶抑制剂量，其化学式为（1）： 1 其中A为—OH或—NRR′。这些抑制剂在治疗肿瘤、动脉粥样硬化和慢性炎症性疾病方面是有用的。 本发明还提供了新颖的化学式（1a）中A为—NRR′的N-羧甲基取代苯并内酰胺。
• 3-(thio-substitutedamido)-lactams useful as inhibitors of matrix metalloproteinase
  申请人：Avantis Pharmaceuticals Inc.

  公开号：US06262080B1

  公开（公告）日：2001-07-17

  The present invention provides novel thio-substitutedamido lactam derivatives of the formula useful in as inhibitors of matrix metallo-proteinases (MMPs).

  本发明提供了一种新型的硫代氨基内酰胺内酯衍生物，其化学式为，可用作基质金属蛋白酶（MMPs）的抑制剂。
• 1-Carboxymethyl-2-oxo-azepan derivatives useful as selective inhibitors of MMP-12
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06770640B1

  公开（公告）日：2004-08-03

  The present invention relates to certain novel 1-carboxymethyl-2-oxo-azepan derivatives of the formula useful as inhibitors of matrix metalloproteinases (MMPs). The compounds of formula (1) are especially useful as selective inhibitors of MMP-12. Pharmaceutical compositions containing said compounds as well as methods of treating various disease states responding to inhibition of matrix metalloproteinase are also claimed herein.

  本发明涉及某些新型的1-羧甲基-2-氧代-氮丙烷衍生物，其化学式如下，用作基质金属蛋白酶（MMPs）的抑制剂。化合物的化学式（1）特别适用于作为MMP-12的选择性抑制剂。本文还声明了含有上述化合物的药物组合物以及治疗对基质金属蛋白酶抑制有响应的各种疾病状态的方法。
• 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase
  申请人：Warshawsky Alan M.

  公开号：US06953788B1

  公开（公告）日：2005-10-11

  The present invention relates to certain novel 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase. Pharmaceutical compositions containing said compounds as well as methods of treating various disease states responding to inhibition of matrix metalloproteinase are also claimed herein.

  本发明涉及某些新型3-巯基乙酰氨基-1,5-取代-2-氧杂癸烷衍生物，其可作为基质金属蛋白酶抑制剂。本文还声明了含有该化合物的药物组合物以及治疗对基质金属蛋白酶抑制有反应的各种疾病状态的方法。